TERMINATION AND ASSET TRANSFER AGREEMENT by and between NOVARTIS PHARMA AG, NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. and ARRAY BIOPHARMA INC. Dated as of November 26, 2014Termination and Asset Transfer Agreement • February 4th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
THIS TERMINATION AND ASSET TRANSFER AGREEMENT, dated as of November 26, 2014 (together with all Schedules and Exhibits attached hereto, this “Agreement”), is made by and among Novartis Pharma AG, a Swiss corporation (“Novartis”), Novartis International Pharmaceutical Ltd., a corporation organized and existing under the laws of Bermuda, for purposes of Articles II, Section 4.1, Section 5.1(d) and Article X only (“NIP”), and Array BioPharma Inc., a Delaware corporation (“Array”).
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • February 4th, 2015 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO.3 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this "Amendment") effective as of October 13, 2014 (the "Amendment Date"), is made by and between Array BioPharma Inc., a Delaware corporation ("Array"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo").
LICENSE AGREEMENTLicense Agreement • February 4th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
All ancillary compounds and materials associated with the development and characterization of ARRY-380 drug product and drug substance; including but not limited to:
